Medical - Devices
Compare Stocks
5 / 10Stock Comparison
BDMD vs HLIT vs VIAV vs NVCR vs LITE
Revenue, margins, valuation, and 5-year total return — side by side.
Communication Equipment
Communication Equipment
Medical - Instruments & Supplies
Communication Equipment
BDMD vs HLIT vs VIAV vs NVCR vs LITE — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Devices | Communication Equipment | Communication Equipment | Medical - Instruments & Supplies | Communication Equipment |
| Market Cap | $68M | $1.38B | $11.81B | $1.92B | $63.74B |
| Revenue (TTM) | $37M | $636M | $1.37B | $674M | $2.49B |
| Net Income (TTM) | $12M | $50M | $-55M | $-173M | $440M |
| Gross Margin | 88.2% | 55.7% | 55.7% | 75.2% | 37.7% |
| Operating Margin | 41.4% | 12.1% | 8.2% | -27.2% | 9.5% |
| Forward P/E | 3.8x | 21.8x | 55.2x | — | 114.4x |
| Total Debt | $21M | $148M | $692M | $290M | $2.61B |
| Cash & Equiv. | $3M | $101M | $424M | $103M | $521M |
BDMD vs HLIT vs VIAV vs NVCR vs LITE — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Dec 21 | May 26 | Return |
|---|---|---|---|
| Baird Medical Inves… (BDMD) | 100 | 18.9 | -81.1% |
| Harmonic Inc. (HLIT) | 100 | 104.4 | +4.4% |
| Viavi Solutions Inc. (VIAV) | 100 | 289.7 | +189.7% |
| NovoCure Limited (NVCR) | 100 | 22.4 | -77.6% |
| Lumentum Holdings I… (LITE) | 100 | 844.1 | +744.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: BDMD vs HLIT vs VIAV vs NVCR vs LITE
Each card shows where this stock fits in a portfolio — not just who wins on paper.
BDMD carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- Dividend streak 1 yrs, beta 1.15
- Lower volatility, beta 1.15, Low D/E 52.5%, current ratio 1.77x
- Beta 1.15, current ratio 1.77x
- Lower P/E (3.8x vs 114.4x)
HLIT plays a supporting role in this comparison — it may shine differently against other peers.
VIAV lags the leaders in this set but could rank higher in a more targeted comparison.
Among these 5 stocks, NVCR doesn't own a clear edge in any measured category.
LITE is the #2 pick in this set and the best alternative if growth exposure and long-term compounding is your priority.
- Rev growth 21.0%, EPS growth 104.6%, 3Y rev CAGR -1.3%
- 36.4% 10Y total return vs VIAV's 7.2%
- 21.0% revenue growth vs NVCR's 8.3%
- +12.5% vs BDMD's -65.2%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 21.0% revenue growth vs NVCR's 8.3% | |
| Value | Lower P/E (3.8x vs 114.4x) | |
| Quality / Margins | 33.6% margin vs NVCR's -25.7% | |
| Stability / Safety | Beta 1.15 vs LITE's 2.69, lower leverage | |
| Dividends | Tie | None of these 5 stocks pay a meaningful dividend |
| Momentum (1Y) | +12.5% vs BDMD's -65.2% | |
| Efficiency (ROA) | 18.5% ROA vs NVCR's -16.5%, ROIC 22.6% vs -16.4% |
BDMD vs HLIT vs VIAV vs NVCR vs LITE — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
BDMD vs HLIT vs VIAV vs NVCR vs LITE — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
BDMD leads in 3 of 6 categories
LITE leads 1 • HLIT leads 0 • VIAV leads 0 • NVCR leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
BDMD leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
LITE is the larger business by revenue, generating $2.5B annually — 67.2x BDMD's $37M. BDMD is the more profitable business, keeping 33.6% of every revenue dollar as net income compared to NVCR's -25.7%. On growth, LITE holds the edge at +90.1% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $37M | $636M | $1.4B | $674M | $2.5B |
| EBITDAEarnings before interest/tax | — | $88M | $207M | -$165M | $425M |
| Net IncomeAfter-tax profit | — | $50M | -$55M | -$173M | $440M |
| Free Cash FlowCash after capex | — | $133M | $46M | -$48M | $399M |
| Gross MarginGross profit ÷ Revenue | +88.2% | +55.7% | +55.7% | +75.2% | +37.7% |
| Operating MarginEBIT ÷ Revenue | +41.4% | +12.1% | +8.2% | -27.2% | +9.5% |
| Net MarginNet income ÷ Revenue | +33.6% | +7.8% | -4.0% | -25.7% | +17.7% |
| FCF MarginFCF ÷ Revenue | -24.8% | +21.0% | +3.3% | -7.1% | +16.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -27.3% | +42.8% | +12.3% | +90.1% |
| EPS Growth (YoY)Latest quarter vs prior year | — | -87.5% | -70.2% | -100.0% | +3.3% |
Valuation Metrics
BDMD leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
At 3.8x trailing earnings, BDMD trades at a 100% valuation discount to LITE's 2412.9x P/E. On an enterprise value basis, BDMD's 5.1x EV/EBITDA is more attractive than LITE's 859.4x.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $68M | $1.4B | $11.8B | $1.9B | $63.7B |
| Enterprise ValueMkt cap + debt − cash | $86M | $1.4B | $12.1B | $2.1B | $65.8B |
| Trailing P/EPrice ÷ TTM EPS | 3.80x | 37.21x | 340.33x | -13.80x | 2412.94x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 21.80x | 55.18x | — | 114.43x |
| PEG RatioP/E ÷ EPS growth rate | — | — | 74.57x | — | — |
| EV / EBITDAEnterprise value multiple | 5.13x | 18.93x | 90.43x | — | 859.43x |
| Price / SalesMarket cap ÷ Revenue | 1.84x | 2.03x | 10.89x | 2.92x | 38.75x |
| Price / BookPrice ÷ Book value/share | 1.20x | 3.10x | 14.77x | 5.51x | 54.76x |
| Price / FCFMarket cap ÷ FCF | — | 26.13x | 190.52x | — | — |
Profitability & Efficiency
BDMD leads this category, winning 7 of 9 comparable metrics.
Profitability & Efficiency
BDMD delivers a 33.0% return on equity — every $100 of shareholder capital generates $33 in annual profit, vs $-51 for NVCR. HLIT carries lower financial leverage with a 0.32x debt-to-equity ratio, signaling a more conservative balance sheet compared to LITE's 2.30x. On the Piotroski fundamental quality scale (0–9), HLIT scores 7/9 vs BDMD's 2/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +33.0% | +11.2% | -6.9% | -50.8% | +30.7% |
| ROA (TTM)Return on assets | +18.5% | +6.5% | -2.3% | -16.5% | +8.5% |
| ROICReturn on invested capital | +22.6% | +9.3% | +5.5% | -16.4% | -4.3% |
| ROCEReturn on capital employed | +37.8% | +11.2% | +4.9% | -28.9% | -4.8% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 7 | 5 | 5 | 7 |
| Debt / EquityFinancial leverage | 0.53x | 0.32x | 0.89x | 0.85x | 2.30x |
| Net DebtTotal debt minus cash | $18M | $47M | $269M | $187M | $2.1B |
| Cash & Equiv.Liquid assets | $3M | $101M | $424M | $103M | $521M |
| Total DebtShort + long-term debt | $21M | $148M | $692M | $290M | $2.6B |
| Interest CoverageEBIT ÷ Interest expense | 26.55x | 12.92x | 2.70x | -96.80x | 9.62x |
Total Returns (Dividends Reinvested)
LITE leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in LITE five years ago would be worth $107,656 today (with dividends reinvested), compared to $875 for NVCR. Over the past 12 months, LITE leads with a +1247.8% total return vs BDMD's -65.2%. The 3-year compound annual growth rate (CAGR) favors LITE at 165.2% vs BDMD's -43.4% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +38.8% | +22.6% | +181.3% | +28.3% | +131.2% |
| 1-Year ReturnPast 12 months | -65.2% | +38.1% | +466.6% | +1.1% | +1247.8% |
| 3-Year ReturnCumulative with dividends | -81.9% | -8.9% | +461.0% | -75.7% | +1764.2% |
| 5-Year ReturnCumulative with dividends | -80.8% | +69.4% | +212.0% | -91.3% | +976.6% |
| 10-Year ReturnCumulative with dividends | -80.8% | +269.9% | +715.5% | +30.3% | +3635.5% |
| CAGR (3Y)Annualised 3-year return | -43.4% | -3.1% | +77.7% | -37.6% | +165.2% |
Risk & Volatility
Evenly matched — BDMD and HLIT each lead in 1 of 2 comparable metrics.
Risk & Volatility
BDMD is the less volatile stock with a 1.15 beta — it tends to amplify market swings less than LITE's 2.69 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. HLIT currently trades 99.2% from its 52-week high vs BDMD's 25.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.15x | 1.51x | 1.54x | 2.20x | 2.69x |
| 52-Week HighHighest price in past year | $7.26 | $12.38 | $60.43 | $20.06 | $1021.00 |
| 52-Week LowLowest price in past year | $0.76 | $7.80 | $8.87 | $9.82 | $60.38 |
| % of 52W HighCurrent price vs 52-week peak | +25.6% | +99.2% | +84.5% | +83.9% | +87.4% |
| RSI (14)Momentum oscillator 0–100 | 47.5 | 76.9 | 66.7 | 69.8 | 58.8 |
| Avg Volume (50D)Average daily shares traded | 960K | 1.1M | 6.3M | 1.5M | 6.4M |
Analyst Outlook
Evenly matched — BDMD and VIAV each lead in 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: HLIT as "Hold", VIAV as "Buy", NVCR as "Buy", LITE as "Buy". Consensus price targets imply 99.0% upside for NVCR (target: $34) vs -36.8% for VIAV (target: $32).
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Hold | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | — | $12.50 | $32.25 | $33.50 | $643.18 |
| # AnalystsCovering analysts | — | 19 | 19 | 15 | 24 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | — |
| Dividend StreakConsecutive years of raises | 1 | — | 1 | — | 0 |
| Dividend / ShareAnnual DPS | — | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +2.2% | +0.1% | 0.0% | +0.1% |
BDMD leads in 3 of 6 categories (Income & Cash Flow, Valuation Metrics). LITE leads in 1 (Total Returns). 2 tied.
BDMD vs HLIT vs VIAV vs NVCR vs LITE: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is BDMD or HLIT or VIAV or NVCR or LITE a better buy right now?
For growth investors, Lumentum Holdings Inc.
(LITE) is the stronger pick with 21. 0% revenue growth year-over-year, versus 8. 3% for NovoCure Limited (NVCR). Baird Medical Investment Holdings Limited (BDMD) offers the better valuation at 3. 8x trailing P/E, making it the more compelling value choice. Analysts rate Viavi Solutions Inc. (VIAV) a "Buy" — based on 19 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — BDMD or HLIT or VIAV or NVCR or LITE?
On trailing P/E, Baird Medical Investment Holdings Limited (BDMD) is the cheapest at 3.
8x versus Lumentum Holdings Inc. at 2412. 9x. On forward P/E, Harmonic Inc. is actually cheaper at 21. 8x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — BDMD or HLIT or VIAV or NVCR or LITE?
Over the past 5 years, Lumentum Holdings Inc.
(LITE) delivered a total return of +976. 6%, compared to -91. 3% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: LITE returned +36. 4% versus BDMD's -80. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — BDMD or HLIT or VIAV or NVCR or LITE?
By beta (market sensitivity over 5 years), Baird Medical Investment Holdings Limited (BDMD) is the lower-risk stock at 1.
15β versus Lumentum Holdings Inc. 's 2. 69β — meaning LITE is approximately 135% more volatile than BDMD relative to the S&P 500. On balance sheet safety, Harmonic Inc. (HLIT) carries a lower debt/equity ratio of 32% versus 2% for Lumentum Holdings Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — BDMD or HLIT or VIAV or NVCR or LITE?
By revenue growth (latest reported year), Lumentum Holdings Inc.
(LITE) is pulling ahead at 21. 0% versus 8. 3% for NovoCure Limited (NVCR). On earnings-per-share growth, the picture is similar: Viavi Solutions Inc. grew EPS 225. 0% year-over-year, compared to -54. 2% for Harmonic Inc.. Over a 3-year CAGR, HLIT leads at 10. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — BDMD or HLIT or VIAV or NVCR or LITE?
Baird Medical Investment Holdings Limited (BDMD) is the more profitable company, earning 33.
6% net margin versus -20. 8% for NovoCure Limited — meaning it keeps 33. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BDMD leads at 41. 4% versus -23. 5% for NVCR. At the gross margin level — before operating expenses — BDMD leads at 88. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is BDMD or HLIT or VIAV or NVCR or LITE more undervalued right now?
On forward earnings alone, Harmonic Inc.
(HLIT) trades at 21. 8x forward P/E versus 114. 4x for Lumentum Holdings Inc. — 92. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NVCR: 99. 0% to $33. 50.
08Which pays a better dividend — BDMD or HLIT or VIAV or NVCR or LITE?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is BDMD or HLIT or VIAV or NVCR or LITE better for a retirement portfolio?
For long-horizon retirement investors, Viavi Solutions Inc.
(VIAV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+715. 5% 10Y return). NovoCure Limited (NVCR) carries a higher beta of 2. 20 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (VIAV: +715. 5%, NVCR: +30. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between BDMD and HLIT and VIAV and NVCR and LITE?
These companies operate in different sectors (BDMD (Healthcare) and HLIT (Technology) and VIAV (Technology) and NVCR (Healthcare) and LITE (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: BDMD is a small-cap high-growth stock; HLIT is a small-cap quality compounder stock; VIAV is a mid-cap quality compounder stock; NVCR is a small-cap quality compounder stock; LITE is a mid-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.